H. Lundbeck A/S
http://www.lundbeck.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From H. Lundbeck A/S
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: summer ADC dealmaking continues apace; a look at cell therapies in Japan; Pfizer’s new US digital consumer platform; Galapagos’s US point of care CAR-T study; and Novartis partners with Lindy on biologics delivery.
Honey, I Shrunk The Drugs: Novartis, Lindy Partner On Biologics Delivery
Novartis is paying Lindy potentially more than $900m to use its technology for making intravenous biologics available for subcutaneous injection using autoinjectors.
Amgen Gets Into Position For MariTide Development
In an interview, CFO Peter Griffith pointed to a boost in capex to build out capacity for the obesity drug, which the company expects to move into Phase III development in the near term.
Viking Plans To Go Directly To Phase III With Obesity Drug
In its Q2 earnings call, the biotech expressed optimism about developing VK2735 as a monthly injection, with an oral version moving into Phase II. An EOP2 meeting for its MASH drug is expected in Q4.
Company Information
- Industry
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Abide Therapeutics Inc.
- Alder Biopharmaceuticals, Inc.
- Chelsea Therapeutics International, Ltd.
- Lundbeck La Jolla Research Center
- Lundbeck Seattle Biopharmaceuticals
- Ovation Pharmaceuticals, Inc
- Saegis Pharmaceuticals, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice